CollPlant Biotechnologies (CLGN) Total Current Liabilities (2017 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Total Current Liabilities came in at $2.7 million in Q4 2025, down 10.03% YoY from $3.0 million in Q4 2024, and up 1.52% on a QoQ basis from $2.6 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Total Current Liabilities (2017 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 9 years of Total Current Liabilities data on file, last reported at $2.7 million in Q4 2025.
- Quarterly Total Current Liabilities fell 10.03% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (down 10.03% YoY) and the FY2025 annual result came in at $2.7 million, down 10.03% from the prior year.
- Total Current Liabilities climbed to $2.7 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $3.4 million in Q1 2024 to a low of $2.3 million in Q3 2022.
- A 5-year average of $2.9 million and a median of $2.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities surged 34.79% — and 2022, when it decreased 22.65%.
- Tracing CLGN's Total Current Liabilities over 5 years: stood at $3.0 million in 2021, then grew by 3.02% to $3.1 million in 2022, then rose by 4.7% to $3.3 million in 2023, then slipped by 8.64% to $3.0 million in 2024, then fell by 10.03% to $2.7 million in 2025.
- The last three Total Current Liabilities figures came in at $2.7 million (Q4 2025), $2.6 million (Q3 2025), and $2.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.67 Mn |
| Sep 30, 2025 | 2.63 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 2.63 Mn |
| Jun 30, 2023 | 2.78 Mn |
| Mar 31, 2023 | 2.92 Mn |
| Dec 31, 2022 | 3.11 Mn |
| Sep 30, 2022 | 2.33 Mn |
| Jun 30, 2022 | 2.36 Mn |
| Mar 31, 2022 | 2.61 Mn |
| Dec 31, 2021 | 3.01 Mn |
| Sep 30, 2021 | 2.52 Mn |
| Jun 30, 2021 | 2.93 Mn |
| Mar 31, 2021 | 3.38 Mn |
| Dec 31, 2020 | 3.39 Mn |